CVS Health (NYSE:CVS) Earns “Buy” Rating from Royal Bank of Canada

CVS Health (NYSE:CVS)‘s stock had its “buy” rating restated by Royal Bank of Canada in a report issued on Thursday, AnalystRatings.com reports.

Several other brokerages have also issued reports on CVS. UBS Group cut their target price on shares of CVS Health from $85.00 to $79.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. ValuEngine downgraded shares of CVS Health from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 30th. Robert W. Baird increased their price target on shares of CVS Health from $62.00 to $66.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Morgan Stanley increased their price target on shares of CVS Health from $71.00 to $77.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Tigress Financial reiterated a “buy” rating on shares of CVS Health in a research report on Friday, April 24th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.35.

NYSE CVS traded down $1.67 during trading hours on Thursday, hitting $61.47. The company’s stock had a trading volume of 2,224,746 shares, compared to its average volume of 7,487,146. CVS Health has a 12 month low of $52.04 and a 12 month high of $77.03. The company’s 50 day simple moving average is $65.02 and its two-hundred day simple moving average is $65.65. The company has a market cap of $83.55 billion, a P/E ratio of 11.19, a price-to-earnings-growth ratio of 1.43 and a beta of 0.76. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.99 and a quick ratio of 0.70.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $1.91 EPS for the quarter, topping the consensus estimate of $1.63 by $0.28. The company had revenue of $66.76 billion during the quarter, compared to the consensus estimate of $64.11 billion. CVS Health had a return on equity of 15.17% and a net margin of 2.76%. CVS Health’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the company earned $1.62 EPS. As a group, research analysts predict that CVS Health will post 7.1 earnings per share for the current fiscal year.

In related news, EVP Alan Lotvin bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average cost of $63.14 per share, with a total value of $315,700.00. Following the completion of the purchase, the executive vice president now owns 15,161 shares of the company’s stock, valued at approximately $957,265.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP James David Clark sold 6,234 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $65.00, for a total transaction of $405,210.00. Following the transaction, the senior vice president now directly owns 4,817 shares of the company’s stock, valued at $313,105. The disclosure for this sale can be found here. 0.46% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Williams Jones Wealth Management LLC. grew its stake in CVS Health by 0.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 15,527 shares of the pharmacy operator’s stock valued at $1,154,000 after acquiring an additional 143 shares in the last quarter. Meiji Yasuda Life Insurance Co boosted its position in CVS Health by 0.9% during the 4th quarter. Meiji Yasuda Life Insurance Co now owns 16,214 shares of the pharmacy operator’s stock valued at $1,205,000 after acquiring an additional 152 shares in the last quarter. Abbrea Capital LLC boosted its position in shares of CVS Health by 2.6% in the 1st quarter. Abbrea Capital LLC now owns 6,198 shares of the pharmacy operator’s stock worth $368,000 after purchasing an additional 159 shares in the last quarter. Advisory Alpha LLC boosted its position in shares of CVS Health by 25.2% in the 1st quarter. Advisory Alpha LLC now owns 799 shares of the pharmacy operator’s stock worth $49,000 after purchasing an additional 161 shares in the last quarter. Finally, Ballast Advisors LLC boosted its position in shares of CVS Health by 3.0% in the 1st quarter. Ballast Advisors LLC now owns 5,836 shares of the pharmacy operator’s stock worth $346,000 after purchasing an additional 169 shares in the last quarter. 76.09% of the stock is owned by institutional investors.

About CVS Health

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

See Also: Monthly Dividend Stocks

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.